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The proliferative capacity of tumor cells is a fundamental feature of growing tumors. Ki-67 is a general proliferation marker [4] widely used to characterize malignant lesions including those of the cervix. The Ki-67 staining into the upper epithelium layers accomplishes the severity of cervical lesions [2, 5] , but the exact nuclear function of Ki-67 antigen is largely unknown [4] . Thus, detecting markers directly involved in DNA replication might be a more precise way to evaluate proliferative behavior in dysplastic and neoplastic processes.
Minichromosome maintenance (MCM) proteins (2-7) complex consists of six subunits with essential functions in initiation and elongation of DNA replication [6] . Additionally, it has only been demonstrated in replicating cells [7] . MCM7 was reported to be associated with tumor formation, progression and malignant conversion [8] . It has also been considered a valuable proliferation marker in several cancer types, such as oral, prostatic, colonic [9] , lung-adenocarcinoma and cervical [8] . Few studies investigated the MCM7 expression in human cervix tissues [7, 8] , and there were no reports that comparatively evaluated the MCM7 expression with those originating from the most commonly used p16 and Ki-67 markers. The purpose of this study was to compare the potential of these three nuclear proteins as biomarkers for cervical disease progression.
MATERIALS AND METHODS

Tissue samples
Twenty paraffin-embedded cervical samples (5 normal epithelium, 5 CIN I, 5 CIN II, and 5 CIN III cases) were obtained from the archive of a large histopathological diagnostic service laboratory. This study was approved by the National Council of Ethics in Research.
Indirect immuno-fluorescence
Serial sections (5 µM-thick) were immersed in xylene, rehydrated, heated in water-bath for 30 minutes for antigen retrieval, and blocked with 2% phosphate-buffered saline and bovine serum albumin (PBS/BSA) for 60 minutes at room temperature (RT). Sections were incubated overnight at 4 o C with the primary antibodies: p16 mouse-monoclonal antibodyclone JC8 (1:800, LabVision, Fremont, CA, USA), Ki-67 rabbitpolyclonal antibody-clone H-300 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MCM7 mouse-monoclonal antibody, clone DCS-141 (1:1000, Abcam, Cambridge, MA, USA). Sections were next incubated (1 hour-RT) with secondary antibodies: Cy2-Streptavidin-conjugated anti-mouse antibody (Molecular-Probes Inc., Eugene, OR, USA) and Cy5-conjugated anti-rabbit antibody (Molecular-Probes Inc.), washed, mounted (Hydramount, National Diagnostics, Atlanta, GA, USA) and examined at high-magnification fields (40x) by scanning confocal microscopy (Carl Zeiss LSM/510Meta, Carl Zeiss Jena, Germany). Strong nuclear and cytoplasmic labeling was considered a p16 positive-reaction; the Ki-67/MCM7 markers' positivity was based on strong nuclear labeling detection. Quantitative determination of p16 immuno-positive areas and the number of positive cells and/or nuclei for all markers was performed by the KS-300/Image Analyzer Carl Zeiss. Spearman's correlation statistical-technique was used for analyzing the association between the biomarker's expression and the cervicalepithelium histological grade. Pearson's correlation statisticaltechnique was used for comparative-evaluation between p16 positive cells/nuclei and Ki-67/MCM7 positive nuclei. A p<0.05 was considered statistically significant. The quantitative results were also expressed in a semi-quantitative scale, by using previously published scoring-criteria [2] . The Ki-67 and MCM7 labeling indexes (LIs) were calculated by dividing the number of positive nuclei by the total nuclei number [9] .
RESULTS
Normal tissues did not show any positive areas or immunoreactive cells for p16 (Table 1) . However an increasing number of p16 immuno-labeled areas was observed along with the severity of cervical disease (Table 1) . A similar result was verified when these values were expressed in a semi-quantitative scale: the majority of CIN I, II, and III samples exhibited a growing pattern of p16 positive areas (Table 2 ). In accordance with the quantitative p16 area analysis, an increase was observed in p16 positive cells according to the CIN severity degree (Table  1) .
However, when these results were semi-quantitatively expressed the p16 immuno-labeling analysis within the CIN groups showed greater variability ( Table 2) . Regarding the Ki-67 results, the number of Ki-67 positive nuclei increased from normal to CIN II epithelium, but no notable differences were observed between CIN II and III values (Table 1) . Most normal, CIN I and II tissue samples, showed a similar Ki-67 labeling pattern (+2 score), whereas the majority of CIN III samples scored as +3. A growing expression of MCM7 was observed from normal to CIN III samples, with the highest MCM7 expression values detected in CIN III cases (Table 1) .
Accordingly, most of normal and all the CIN I samples were www.ejgo.org 13 MCM7 scored as +2, while the majority (60%) of CIN II and III samples were scored as +3 and +4 ( According to the biomarkers' expression distribution through the cervical epithelium, all the normal cervical tissue samples were negative for p16 and showed Ki-67 and MCM7 labeling in the lower (1/3) basal epithelium (Fig. 1) . Forty percent of CIN I samples exhibited p16 immuno-expression in the basal layer, while 100% of CIN II and III samples showed labeling of 2/3 and 3/3 of the epithelium. Concerning the Ki-67 expression topology, 60% of CIN I and 100% of CIN II samples showed 2/3 of the epithelium staining while 60% of CIN III exhibited labeling in 3/3 of the epithelium. Most of the normal and CIN I tissue samples expressed MCM7 in the 1/3 basalepithelium, whereas the majority of CIN II and III cases showed MCM labeling in 2/3 of the epithelium.
DISCUSSION
In this study we have shown, using a quantitative-evaluation approach, that p16, Ki-67, and MCM7 markers are significantly correlated with cervical lesion progression. Several studies con- 14 www.ejgo.org firmed negative to minimal p16-staining in normal/reac tive cer vical biopsies, with considerable variability in the CIN grade samples presenting strong p16 immuno-reactivity [1, 3] . Therefore, quantitative analysis of p16 areas and/or cells seemed to be a better approach when performing the categorization of CIN groups than conventional semi-quantitative evaluation. Additionally, we performed a comparative analysis between Ki-67 and MCM7 proliferation-related proteins as CIN progression markers. Ki-67 positivity extending to 2/3 of the epithelium was reported to be associated with increasing cervical dysplasia degree [2, 5] . However, this marker specificity is low [2] , Ki-67 expression-levels can be altered by external factors and there is no evidence that this protein is essential for cell proliferation [4] . Here, we observed a higher expression of both Ki-67 and MCM7 in high-grade when compared to low-grade lesions or normal cervical-epithelium. Few studies have examined MCMs as proliferation markers in cervical disease and have focused mostly in analyzing the MCM2/5 expression. In only one study the MCM7 staining topology-pattern was evaluated in cervical, normal and affected tissues [8] . Our results are concordant with this report, since a significant association between the p16, Ki-67, and MCM7 topology-patterns expression and human-cervical disease progression was observed. Other reports showed that MCM7 labeling-indexes were consistently higher than Ki-67 LIs in several cancer types [8, 9] . Previous studies have shown that, additionally to proliferative cells, MCM proteins were ex pre ssed in potent or early-proliferating cells [6] . Thus, these observations may imply that, Ki-67 does not label all proliferating cells of some tumors [4] . We believe that MCM7 offers a great advantage over other 
www.ejgo.org 15
proliferating biomarkers, since it is not expressed in cells undergoing DNA repair [6] and exhibits a higher sensitivity to identify abnormal precursor cells than Ki-67/PCNA [8] . Consequently, MCM7 is regarded an excellent candidate marker for cancer screening, surveillance, and prognosis [7, 9] . In a prospective study involving the analysis of cervical smear samples from 455 Indian women, the combined use of MCM2/5-staining and Pap-counterstaining disclosed 10 previously missed cases of biopsy-proven cervical cancer or precancer when using the standard Pap-staining [10] . Although this study was focused on the evaluation of MCM7 as an indicator of progressive-cervical disease in tissue samples, the biomarker expression demonstrated a satisfactory correlation with CIN progression, suggesting that MCM7 could be used as a valuable tool for improving the diagnosis and screening of pre-malignant lesions and cervical cancer.
